InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Updated Platform Includes AI Capabilities, Supports Essential Reskilling of Workers
May 11, 2023
Amesite (NASDAQ: AMST) newest version of its eLearning software, version 6 (“V6”), includes generative artificial intelligence (“AI”) capabilities powered by GPT-4, the technology that supports ChatGPT Plus and Microsoft’s new Bing browser. The company provides its white-label, scalable platform to a range of institutions such as universities, museums, businesses, and government agencies, to help them […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Announces Participation at Upcoming Sidoti Virtual Investor Conference
May 10, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, will be part of the Sidoti May Micro-Cap Virtual Conference, which is slated for May 10–11, 2023. The company announced that its founder and CEO Dr. Ann Marie Sastry will present during the two-day event. Sastry’s […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Renews Partnership with Michigan Works! Southeast
April 27, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, today announced it is extending its partnership with Michigan Works! Southeast (“MWSE”), a longtime leader in upskilling the workforces of Southeast Michigan. The continued partnership will deliver upskilling needs, specifically training on artificial intelligence technologies for the Michigan workforce on MWSE’s proprietary […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
April 18, 2023
The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars – the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of keynotes from life science executives, fireside chats, panel discussions, and presentations that allowed […]
InvestorNewsBreaks – Amesite Inc.’s (NASDAQ: AMST) Platform, Generative AI Helping Customers Deliver Education Offerings at Scale
April 17, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, is setting up key partnerships with universities to provide upskilling and reskilling courses to their students. The company recently expanded its alliance with the National Association for Equal Opportunity in Higher Education (“NAFEO”), the college membership […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) CEO Serving as Panelist at National Action Network 2023 Convention
April 14, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announced that its founder and CEO Dr. Ann Marie Sastry is serving as a panelist at the National Action Network 2023 Convention on Friday, April 14, 2023, representing National Association for Equal Opportunity in Higher Education […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring
April 14, 2023
Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV), recently presented at the 17th annual BIO-Europe Spring conference in Basel, Switzerland. Hosted by EBD Group, the three-day in-person conference, which was held March 20-22, brought together more than 2,800 executives from biotech, pharma, and finance companies. It not only featured presentations and exhibits from […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) CEO to Attend ASU+GSV Summit
April 13, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, will be represented at the upcoming ASU+GSV Summit. The company announced that Amesite founder and CEO Dr. Ann Marie Sastry will be attending the ASU+GSV Summit; she will also be available for one-on-one meetings with other […]
InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
April 3, 2023
BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Launches V6 Platform Featuring GPT-4 Powered Functionality
April 3, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, today unveiled its Version 6.0 platform with enhanced and new features. With expanded AI capabilities, the platform is powered by GPT-4 – the same technology behind ChatGPT Plus and Microsoft’s New Bing. “Advancements in generative AI […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Announces Expansion of Member Universities to NAFEO Alliance
March 30, 2023
Amesite (NASDAQ: AMST) is a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets. The company today announced that new member universities have joined its collaborative alliance with the National Association for Equal Opportunity in Higher Education (“NAFEO”), the membership and advocacy association of all Historically Black Colleges and […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Eyes Opportunity as a Frontrunner for Integrating ChatGPT
March 20, 2023
Amesite (NASDAQ: AMST), a Detroit-based AI software company, has set out the progress it has made in integrating generative AI into its platform. The release of ChatGPT has showcased capabilities and potential of generative AI, which can produce increasingly sophisticated original content. Companies like Amesite that have exposure to generative AI and e-learning sectors could […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Delivering FERPA and COPPA-Compliant Learning Programs
March 15, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, today announced that its white-label platform is delivering COPPA and FERPA-compliant learning programs for its partners around the nation. Designed to protect children’s safety and personal data, requirements call for parental consent for children under the […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Releases Statement Regarding No Accounts with, Relationship to Silicon Valley Bank
March 14, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform that delivers 99% learner retention for business and education markets, has announced that it does not hold any cash or contain any accounts at Silicon Valley Bank (“SVB”). The company also noted that it has no current or past business relationship […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Regains Compliance with NASDAQ Minimum Bid Price, Other Listing Requirements
March 10, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform that delivers 99% learner retention for business and education markets, has received notice that it has regained compliance with NASDAQ’s minimum bid price requirement of $1.00 per share. The notice also stated that the company meets the stockholders’ equity requirement and […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) CEO Expands Company Owned Stock with Series of Recent Purchases
March 7, 2023
Amesite (NASDAQ: AMST) CEO Ann Marie Sastry has made multiple stock purchases in AMST, an artificial intelligence (“AI”) software company that offers leading eLearning opportunities. According to the Form 4 filed with the Securities and Exchange Commission (“SEC”), Sastry acquired 2,000 shares of common stock, each at $3, for the purchase price of $6,000. This […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Partners with Benedict College to Launch Technology Upskilling Pilot Program
March 2, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform that delivers 99% learner retention for business and education markets, has announced an upskilling pilot project in partnership with Benedict College. According to the announcement, the pilot leverages GPT-3, the latest technological disruptor that powers ChatGPT, through the Amesite platform; the […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) to Provide Video Update for Shareholders
February 27, 2023
Amesite (NASDAQ: AMST) is a leading artificial intelligence software company offering a cloud-based learning platform that delivers 99% learner retention for business and education markets. The company today announced that it will be posting a video shareholder update to its website at 1:00 PM ET on Monday, Feb. 27, 2023. Shareholders should visit https://ibn.fm/Qq6nf to […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants
February 24, 2023
The Food and Drug Administration (“FDA”) has, over the last two years, authorized several drugs as treatments for mild-to-moderate COVID-19 or as pre-exposure prophylaxis (“PrEP”) for the prevention of the disease. Most of these drugs were based on human monoclonal antibody (“mAb”) technology and were designed to boost the immune system by mimicking natural neutralizing […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Shareholders Approve 1-for-12 Reverse Stock Split, Effective Today
February 22, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence (“AI”) software company offering a cloud-based learning platform for education, business and government markets, will effect a 1-for-12 reverse split of its common stock; the reserve split was effective today at open of business. According to the announcement, AMST common stock will trade on a post-split basis on […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Unveils Free Course to Teach Fundamentals of ChatGPT
February 21, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence (“AI”) software company offering a cloud-based learning platform for education, business and government markets, has launched ChatGPT Fundamentals, a free course available on AmesiteEngage, the company’s Learning Community Environment(R). The course will be free to the first 1,000 people who register. According to the announcement, course curriculum covers the […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Launches First Pilot Program Under NAFEO Alliance
February 16, 2023
Amesite (NASDAQ: AMST) and the National Association for Equal Opportunity in Higher Education (“NAFEO”), today announced the launch of the first pilot program through their alliance. Amesite is providing the cross-campus pilot, which offers upskilling in technology, including internet protocols, data privacy and security and cloud computing, to Benedict College, a member of the alliance. […]
InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages
February 15, 2023
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently achieved key milestones. These include the demonstration of statistically significant positive results from a preclinical in-vivo proof-of-concept study of its inhaled anti-COVID-19 nanosized antibodies (“NanoAbs”). “Its lead NanoAb candidate, designed […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) to Expand AI Toolkit with Addition of GPT-3 Powered Functionality
February 14, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform that delivers 99% learner retention for business and education markets, is expanding its platform capabilities. The company announced that it is has added features to its learning platform that leveraging GPT-3, the engine for ChatGPT; the features complement the platform’s existing […]
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference
February 13, 2023
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, took part in the 2023 BIO CEO & Investor Conference held at the Marriott Marquis, New York. The conference, which took place from February 6-8, offered a platform for stakeholders in the […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth
February 8, 2023
Immunotherapeutic product innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) is focused on developing, manufacturing, and commercializing innovative nanosized antibodies (NanoAbs) for the treatment of infectious diseases and autoimmune diseases, stepping up its pursuit of disrupting the monoclonal antibody (“mAb”) market amid forecasts that the global mAb market will grow at a compound annual rate (“CAGR”) of 11.30 […]
InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target
February 6, 2023
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis Capital Corp. The update reflects the strong results from BVXV’s latest animal study indicating that anti-COVID-19 NanoAb can prevent infection. […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study
January 30, 2023
Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional results in the company’s preclinical proof-of-concept study of its inhaled nanosized VHH-antibody (NanoAb) COVID-19 drug (https://ibn.fm/Kz8W4). BiondVax is developing a pipeline of innovative alpaca-derived NanoAb drugs addressing diseases with large underserved medical needs and attractive commercial […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Releases Video Featuring Successful Global Enterprise Learning Solution Case Study
January 25, 2023
Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, released a case study video showing the successful delivery of its global enterprise learning solution for EWIE Group of Companies (“EGC”). In the video, EGC training and quality manager Kasey Braun reports that AMST technology relieved administrative […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
January 23, 2023
According to a new study, new COVID-19 subvariants have become dominant in recent months, rendering some current vaccines and treatments less effective, which could results in a surge of breakthrough infections. To date, the BQ.1, BQ.1.1, XBB, and XBB.1 omicron subvariants are the most immune evasive variants of COVID-19 – causing 72% of new infections […]
InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
January 23, 2023
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss […]
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
January 23, 2023
JERUSALEM, Jan. 23, 2023 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. Using an industry-standard animal […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) to Participate at Upcoming Sidoti Virtual Investor Conference
January 17, 2023
Amesite (NASDAQ: AMST) CEO Dr. Ann Marie Sastry will be presenting at the Sidoti Virtual Investor Conference; the event is scheduled for Jan. 18–19, 2023. A leading artificial intelligence software company, Amesite offers a cloud-based learning platform for business and education markets. Sastry will be presenting on Jan. 18 at 9:15 a.m.; she will also […]
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs
January 17, 2023
Mainland China is experiencing a fresh wave of COVID-19 infections sweeping some of its most populous provinces. The SARS-CoV-2 virus, which causes COVID-19, has been spreading fast since the Chinese government in early December lifted restrictions that were aimed at containing infections (https://ibn.fm/SzDKu). Results of the policy have been dire. Early this year, officials reported […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) CEO Discusses Promising Future in Learning on Benzinga Podcast
January 10, 2023
Amesite’s (NASDAQ: AMST) CEO Dr. Ann Marie Sastry recently sat down for a chat with Benzinga to discuss the Detroit-based company’s past year of successful partnerships and to look ahead to a promising 2023. Dr. Sastry explained how Amesite is an educational technology (“EdTech”) software-as-a-service (“SaaS”) company helping modernize educational systems via its artificial intelligence […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform
January 6, 2023
Calendar year 2022 has been eventful for BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. Recently, the company was covered in a recent research report by Zacks Small-Cap Research (https://ibn.fm/DXlTC). The report valued the company at $57.00 […]
InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus
January 6, 2023
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 […]
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements
January 4, 2023
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products used primarily for the treatment of infectious and autoimmune diseases, recently released key financials for the quarter ending September 30, 2022, and highlighted important business updates (https://ibn.fm/NlQaQ). The company is developing a pipeline of innovative nanosized antibody […]
BiondVax CEO Issues Letter to Shareholders
January 3, 2023
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, today published a letter from its CEO, Amir Reichman, addressing 2022 accomplishments, successful preclinical trial results of the inhaled COVID-19 NanoAb therapy […]
InvestorNewsBreaks – Amesite Inc. (NASDAQ: AMST) Responds to NIST RFI, Positioned to Help US Lead in Semiconductor Space
December 14, 2022
Amesite (NASDAQ: AMST) is a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets. The company today announced that it has submitted a response to the National Institute of Standards and Technology’s (“NIST”) request for information (“RFI”) regarding the design of potential semiconductor and microelectronics innovation manufacturing institutes in […]